Education And Debate
Orphan drugs and the NHS: should we value rarity?
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7523.1016 (Published 27 October 2005) Cite this as: BMJ 2005;331:1016
Cited by...
- 'No One Is Talking About This - rare diseases in childhood
- Defining 'therapeutic value of medicines: a scoping review
- Rare diseases in healthcare priority setting: should rarity matter?
- Value assessment frameworks: who is valuing the care in healthcare?
- Should rare diseases get special treatment?
- Effectiveness, safety and costs of orphan drugs: an evidence-based review
- Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries
- The problem of orphan drugs
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Relating price determination to disease prevalence
- Public healthcare resource allocation and the Rule of Rescue
- The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
- Orphan drugs and the NHS: Fairness in health care entails more than cost effectiveness
- Orphan drugs and the NHS: Consider whom drug regulation is designed to protect
- Commissioning for rare diseases: view from the frontline